Evidence map›Paper›PMID 41704537›Full record

ArticleFrontiers in immunology2025

M2 macrophage infiltration drives tumor progression and identifies a multigene prognostic signature in esophageal cancer.

Guangxia Wei, Chunlin Ye, Yunhe Huang, Zan Luo, Bin Xu, Junyu Li

Abstract read
In one paragraph

Article in Frontiers in immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Guangxia WeiDepartment of Thoracic Surgery, Nanfang Hospital, Southern Medical University, Guangzhou, China.
Chunlin YeDepartment of Thoracic Surgery, the First Affiliated Hospital, Jiangxi Medical College, Nanchang University, Nanchang, China.
Yunhe HuangDepartment of Thoracic Surgery, the First Affiliated Hospital, Jiangxi Medical College, Nanchang University, Nanchang, China.
Zan LuoDepartment of Radiation Oncology, Jiangxi Key Laboratory of Oncology, Jiangxi Cancer Hospital (The Second Affiliated Hospital of Nanchang Medical College), Nanchang, China.
Bin XuDepartment of Thoracic Surgery, the First Affiliated Hospital, Jiangxi Medical College, Nanchang University, Nanchang, China.
Junyu LiDepartment of Radiation Oncology, Jiangxi Key Laboratory of Oncology, Jiangxi Cancer Hospital (The Second Affiliated Hospital of Nanchang Medical College), Nanchang, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Objective: This study aimed to elucidate the mechanistic role of M2 tumor-associated macrophages in esophageal cancer (EC) progression and to construct an M2 macrophage-related gene signature for prognostic prediction. Methods: Integrated analyses of single-cell RNA sequencing (scRNA-seq) and bulk RNA-seq data of EC were performed. scRNA-seq data were processed with Seurat and annotated using SingleR. Immune infiltration was evaluated through ssGSEA and CIBERSORT. Weighted gene coexpression network analysis (WGCNA) was used to identify M2 macrophage-associated modules, and candidate genes were intersected with differentially expressed genes (DEGs). Functional enrichment analyses were performed, and a prognostic risk model was established through multivariate Cox regression analysis. The functional roles of key genes were validated through Results: Twelve cell types were identified by scRNA-seq, with macrophages representing the predominant immune population. M2 macrophages formed the major immunosuppressive subtype and were negatively associated with patient survival. WGCNA and DEG analysis identified 25 M2-related genes, from which a four-gene prognostic signature ( Conclusion: A four-gene M2 macrophage-related prognostic model provides reliable prediction of clinical outcomes in EC. Among these genes,

Indexed as

Esophageal NeoplasmsMacrophagesTumor-Associated MacrophagesAnimalsBiomarkers, TumorCell Line, TumorDisease ProgressionFemaleGene Expression ProfilingGene Expression Regulation, NeoplasticHumansMicePrognosisSingle-Cell Gene Expression AnalysisTranscriptomeTumor MicroenvironmentBiomarkers, Tumorbiomarkersesophageal cancerM2 tumor-associated macrophages (M2 TAMs)microenvironment (TIME)prognostic modelsingle-cell RNA sequencing (scRNA-seq)tumor immune

Identifiers

PMID41704537
PMCPMC12907416

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.